We have a dedicated oncology consulting team of analysts and consultants who deal solely with the complex issues specific to oncology drug development. We provide our clients with the scientific and business acumen required for accurate analysis of competing MOAs and corporate strategies of companies engaged in drug development in the oncology arena.
Our oncology drug development support strategy covers these important areas critical to your success:
Two Labs’ dedicated oncology team provides the expertise required to optimize both oncology launch adoptions and commercial market strategies through a combination of: launch planning support, primary field-intelligence and market insights for oncology therapeutics, competitive pipeline analysis, inclicensing reviews, biomarker analysis, and benchmarking of oncology marketing organizations.
Launch Planning Support
Primary Field-Intelligence & Market Insights for Oncology Therapeutics
Competitive Pipeline Analysis
Inclicensing Reviews
Biomarker Analysis
Benchmarking of Oncology Marketing Organizations
Two Labs’ oncology conference coverage service is uniquely tailored to your specific needs. From preparation, to congress attendance, to wrap-up, our process provides the information and field-intelligence to support a focused and targeted oncology strategy.
Step 1: Congress Preparation
We’ll create a congress schedule that includes presentations of particular interest. A range of cancer indications and issues will be selected for coverage, including key intelligence topics (KITs) important to your strategy.
Step 2: Congress Attendance
Two Labs will attend each conference, gathering key intelligence, including:
Step 3: Congress Wrap Up
The wrap up will include both high-level and detailed information as follows:
To learn more about our extensive range of consulting services for the pharmaceutical and biotechnology industries, contact us.
110 Riverbend Avenue, Suite 100
Powell, OH 43065
Phone: (614) 389-4004
Fax: (866) 259-4324
Email: info@twolabs.com
© Copyright 2023 | Powered by PRISM